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Summary This study was undertaken to determine the prevalence of anti-cardiolipin antibodies (ACLAs) in
patients with malignancy and to investigate a possible association of ACLAs with thromboembolic events in
such patients. The study included 216 patients with solid and non-solid malignancies and an age-matched
control group of 88 healthy subjects. ACLA levels were measured and related to thromboembolic phenomena
(diagnosed by imaging methods) that occurred within 12 months of the diagnosis of cancer. Forty-seven
patients (approximately 22%) with cancer were ACLA positive as compared with only three subjects
(approximately 3%) in the control group (P<0.0001). The ACLA-positive cancer patients had a significantly
higher rate of thromboembolic events than ACLA-negative cancer patients: 13 of 47 (28%) vs 24 of 169
(14%), respectively (P<0.05). High titres of either IgG-ACLA or IgM-ACLA were found in 10 out of 13
ACLA-positive cancer patients with thrombotic complications, but in only 2 out of 34 cancer ACLA-positive
patients without thromboembolic events (P<0.0001). In four cancer patients in whom ACLA levels were
followed ACLA decreased after successful surgery/chemotherapy treatment and remained negative and throm-
boembolic free for 12 months of follow-up. Patients with malignancies show an increased prevalence of
ACLA. Furthermore, ACLA-positive patients, mainly those with high titres, are much more prone to
thromboembolic events.
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The anti-phospholipid antibodies (APLAs), which include the
lupus anticoagulant (LAC) and anti-cardiolipin antibodies
(ACLAs), are a group of antibodies directed predominantly
against negatively charged phospholipids (Hughes, 1983).
Elevated levels of APLAs have been found mainly in sera
from patients with systemic lupus erythematosus (SLE)
(Cervera et al., 1990) as well as other autoimmune diseases or
infectious disorders and in sera from patients with the
'primary' anti-phospholipid syndrome or malignant diseases
(Asherson et al., 1989a; Font et al., 1989, 1991). There have
been many sporadic reports of the association of APLAs, i.e.
ACLAs or LAC, with malignancy such as malignant lym-
phoma (Mills et al., 1977; Maker et al., 1990; Asherson et al.,
1991; Ciaudo et al., 1991; Conlan et al., 1991), plasma cell
dyscrasia (Duhrsen et al., 1987; Bellotti et al., 1989; Watts et
al., 1989; Wisloff et al., 1991; Glaspy, 1992), leukaemia (Dun-
combe et al., 1987; Donner et al., 1992) and lung, colonic,
cervical, prostatic or liver cancer or thymoma (Kozlowski et
al., 1987; Shaukat et al., 1990; Schleider et al., 1976; Meyrier
et al., 1991; Park et al., 1991; Levine et al., 1987). All these
publications were case reports including fewer than 50
patients. However, the growing number of these reports sug-
gests that the association between malignancy and anti-
phospholipid antibodies is not coincidental. Patients with
APLAs are especially prone to recurrent episodes of venous
or arterial thrombosis (Harris et al., 1984; Levine et al., 1987;
Asherson et al., 1989b). Although the association of vascular
thrombosis with malignant diseases (Trousseau's syndrome)
is well known (Sack, et al., 1977; Rickles et al., 1983), the
possible association between malignant diseases, APLAs and
venous or arterial thrombosis has not been investigated, to
the best of our knowledge, in a large prospective study. Our
investigation is the largest study to evaluate the incidence of
ACLAs in patients with malignancy, and its association with
the development of thromboembolic (TE) events.
Patients and methods
Study design and subjects
The subjects of this study were 241 consecutive patients with
biopsy/cytology-proven neoplastic disorders who were admit-
ted within 1 year after diagnosis to the Departments of
Internal Medicine 'A', Surgery, Gynecology or Urology at
the Bnai-Zion Medical Center and to the Department of
Oncology at the General Italian Hospital, Haifa, Israel,
between 1 May 1991 and 31 January 1994.
Twenty-five patients were excluded: three with recurrent
chronic infections, four with autoimmune diseases, four with
chronic inflammatory diseases and 14 in whom the diagnosis
of thromboembolism was not verified by imaging techni-
ques.
Our study thus consisted of 216 patients, whose charac-
teristics are listed in Table I. None of them was admitted for
TE events. Ninety-one of these patients were studied before
the initiation of any cytotoxic or radiation treatments,
whereas the remaining 125 patients were studied 3 months
after such treatments were ended.
The control group included 88 age-matched subjects, all
consecutively admitted to the Department of Internal
Medicine 'A' at the Bnai Zion Medical Center for observa-
tion of chest pain. None of these subjects suffered from an
acute coronary event, infection, chronic inflammation, malig-
nancy, autoimmune diseases or primary anti-phospholipid
syndrome or had an abnormal ECG or abnormal laboratory
Table I Gender, age and ethnic profile of 216 cancer patients
Men 117
Women 99
Age range (years) 21-89
Mean age (years ± s.d.) 67 ± 13
Ethnic groups
Ashkenazi Jews 110
Sephardi Jews 60
Arabs 46
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analysis, and they were therefore considered to be heal-
thy.
Patients were diagnosed as suffering from thromboem-
bolism (one or more events per patient) when (1) each event
occurred within 12 months after the diagnosis of malignancy
and (2) it was detected by clinical symptoms and signs and
was confirmed by ventilation-perfusion radionucleotide lung
scan (pulmonary embolism, PE); contrast or radioisotopic
phlebography or Doppler ultrasound (deep vein thrombosis,
DVT); neurological signs lasting >24 h with evidence of
infarction in an anatomically consistent territory on com-
puterised tomography (CT) or magnetic resonance imaging
(MRI) (cerebral ischaemic strokes); neurological signs or
symptoms lasting <24 h and fulfilling the criteria of the
classification of cerebrovascular diseases of The National
Institute of Neurological Disorders and Strokes (Whisnant,
1990) (cerebral transient ischaemic attacks, TIAs); contrast
arteriography (peripheral arterial thrombosis).
Prophylactic anticoagulation
All confirmed ACLA-positive TE patients were immediately
started on prophylactic anticoagulation for secondary
prevention of thrombosis: heparin was given intravenously
for 3 days, followed by warfarin treatment [international
normalized ratio (INR) 2.0-2.9].
Anti-cardiolipin antibody assay
Anti-cardiolipin antibodies (ACLAs) (IgG and IgM isotype)
were measured in serum stored at -20°C by an enzyme-
linked immunosorbent assay (ELISA), as described by
Gharavi et al. (1987). Results were expressed in IgG phos-
pholipid (GPL) and IgM phospholipid (MPL) units accord-
ing to the recommendation developed at the 1986 Workshop
on Standardization and Interpretation of Anticardiolipin
Test. Positive results up to 30unitsml-' were considered as
low titres; 30-60 unitsml' as moderate titres; and
>60 unitsml-' as high titres (Harris et al., 1987). All ACLA
determinations were performed blindly at three different
runs, including other unknown sera.
Statistical analysis
Data were analysed on an IBM (mainframe) computer using
SPSS. The differences, regarding the various parameters,
between ACLA-positive and ACLA-negative patients, and
between the study and control groups, were evaluated using
the chi-square or Fisher's exact test when applicable with
level of significance = 0.05.
Results
Out of 216 patients with malignancies, 47 (22%) were ACLA
positive, compared with only three in the control group (3%;
P<0.001). Thirteen out of the 47 ACLA-positive cancer
patients (28%) presented TE events within 12 months after
diagnosis, whereas only 24/169 (14%) ACLA-negative cancer
patients had thromboembolism (P<0.05) (see ACLA
prevalence in all malignancy types in Table II).
Out of the 47 cancer-ACLA positive patients, 31 were of
IgG isotype, seven were IgM and nine were both (see Table
III). It is evident from this table that the incidence of throm-
boembolism showed no correlation with low/moderate titres
of ACLA, regardless of isotype (only 3/13 experienced TE
events), whereas thromboembolism was present mainly in
patients with high ACLA titres, since 10/13 (77%) patients
with thromboembolism demonstrated high ACLA titres,
whereas only 2/34 (6%) patients without thromboembolism
had high titres (P<0.0001).
We did not observe any risk factors (such as family history
of TE, medication, catheter usage), which could explain
thromboembolism in ACLA-positive patients. No statistical
difference is observed when ACLA prevalence and throm-
boembolism occurrence are compared with regard to type of
cancer, the extent of disease and tumour burden.
In addition, no difference is observed with regard to
ACLA positivity and TE events when the group of patients
analysed before treatment is compared with that analysed 3
months after (data not shown).
Table III Thromboembolism/non-thromboembolism in ACLA
positive cancer patients (n = 47)
ACLA titres TE (n = 13) Non-TE (n = 134)
Low
IgG 2 9
IgM - 2
IgG + M 3
Total 2 (15%) 14 (41%)
Moderate
IgG 11
IgM 2
IgG+M 1 5
Total 1 (8%) 18 (53%)
High
IgG 7 2
IgM 3 -
IgG + M -
Total 10 (77%) 2 (6%)
Table II Malignancy type and ACLA prevalence in 216 patients
Number ofpatients ACLA positive (%)
Solid tumours
Colorectal carcinoma
Lung carcinoma
Pancreatic carcinoma
Breast carcinoma
Prostatic carcinoma
Metastatic carcinoma (unknown origin)
Ovarian carcinoma
Transitional cell carcinoma of urinary bladder
Primary brain tumour (glioblastoma)
Melanoma
Renal cell carcinoma
Gastric carcinoma
Others
Haematological malignancies
Non-Hodgkin lymphoma
Multiple myeloma
Chronic lymphatic leukaemia
Hodgkin lymphoma
Chronic myeloid leukaemia
Acute lymphatic leukaemia
Waldenstrom's macroglobulinaemia
Hairy cell leukaemia
7 (20%)
5 (18%)
4 (33%)
3 (15%)
3 (19%)
3 (28%)
2 (28%)
39
28
12
20
16
12
7
8
2
3
3
4
11
23
12
9
2
2
1
1
1 (25%)
3 (27%)
9
4
2
(39%)
(33%)
(22%)
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In four patients (two with colonic cancer, one with bron-
chogenic carcinoma and one with high-grade non-Hodgkin's
lymphoma), the levels of ACLA decreased after successful
surgical treatment (in the first three patients) and combina-
tion chemotherapy in the fourth patient. A decline in the
ACLA titre was noted 3 months after therapy was initiated,
and remained negative during 12 months of follow-up. The
patient with non-Hodgkin's lymphoma developed PE and
DVT when ACLA level was 145 GPL units ml-'. She was
treated with low molecular weight heparin and combination
chemotherapy until remission was achieved, which lasted for
12 months. During that period IgG-ACLA was within nor-
mal limits. One month before clinical and pathological
relapse was observed, the ACLA titre increased again, coin-
ciding with a massive pulmonary embolism.
In a group of five patients with elevated ACLA titres,
monoclonal gammopathies of IgG isotypes were observed.
Four patients had IgG myeloma and the fifth patient had
non-Hodgkin's lymphoma. In four patients ACLAs were of
IgG isotype; however, in one both IgG- and IgM-ACLA
were elevated.
Discussion
Patients with malignancies have been shown to be at an
increased risk of thromboembolism (Sack et al., 1977; Rickles
et al., 1983; Goldberg et al., 1987). The incidence of clinical
TE episodes in these patients has varied from 1% to 11%
(Minna, 1989), whereas thromboembolism is more often
found on post-mortem examination (Ambrus et al., 1975).
A number of mechanisms have been proposed to explain
the association of malignancy and thrombosis: activation of
clotting factors (Gordon et al., 1975; Naschitz et al., 1993),
tumour interaction with vascular endothelium (Warren and
Vales, 1972; Al-Mondhiry and McGarvey, 1987) and platelet
activation by cancer cells (Bastida and Ordinas, 1988; Nas-
chitz et al., 1993). The increased presence of anti-
phospholipid/anti-cardiolipin antibodies in patients with
cancer may be a contributory factor in the paraneoplastic
development of vascular thrombosis in these patients. These
antibodies are thought to predispose for thrombosis either by
interacting with phospholipids on platelet membrane/vascular
endothelium (Alarcon-Segovia, 1988; Alarcon-Segovia and
Sanchez-Guerrero, 1989), or by inhibiting protein C
activation/prostacyclin formation by endothelial cells (Cariou
et al., 1986; Carreras and Vermylen, 1982).
A possible association between anti-phospholipid
antibodies, malignancy and thrombosis has been suggested
by several authors (Duhrsen et al., 1987; Kozlowski et al.,
1987; Levine et al., 1987; Shaukat and Hughes, 1990; Gruber
and Hochberg, 1991; Donner et al., 1992; Glaspy, 1992) but
has not been examined in a large controlled prospective
study. The present study, in which patients with 29 different
types of malignancies are included, shows a high association
between elevated ACLA and thrombosis in patients with
cancer as compared with the control group. However, the
aetiopathogenetic relationship between malignancy and
ACLA is not clear. The decline in ACLA titre in four of our
patients, as well as in other reported cases (Duncombe et al.,
1987; Levine et al., 1987; Ciaudo et al., 1991) after surgical
resection of the tumour or after successful chemotherapy
may suggest a non-coincidental association between ACLA
and cancer in these patients. Moreover, in one patient, the
reappearance of ACLA was associated with relapse and
recurrent thrombosis. It is not clear, however, if ACLAs
serve only as a tumour marker or play a pathogenetic role in
vascular thrombosis in patients with malignancy. It has been
shown in our study that patients with high ACLA titres are
significantly more prone to TE events than those with low
ACLA titres. Moreover, the ACLA-positive cancer patients
had significantly more TE events than the ACLA-negative
cancer patients. These two findings seem to suggest that
ACLA may play a pathogenetic role in vascular thrombosis,
at least in some cancer patients. The high titre of ACLA in
two patients without clinical thromboembolism might be
explained by the short follow-up period.
Several mechanisms are suggested for the association
between ACLA and the neoplasm:
1. Production of autoantibodies by the immune system as
a response directed primarily against tumour antigens,
as described in autoimmune haemolysis,
Eaton-Lambert syndrome (Lang et al., 1981) or
cerebellar degeneration (Greenlee and Brashear, 1983)
in cancer patients. This autoimmune response could be
directed against solid tumour antigens or it could be
part of the well-known association between autoimmune
phenomena and malignant lymphoproliferative diseases
(Goldenburg et al., 1969; Miller, 1967).
The decrease in lupus anticoagulants caused by cor-
ticosteroid treatment, as reported in a patient with
inoperable adenocarcinoma of the lung (Kozlowski et
al., 1987), further supports the 'autoimmune'
hypothesis. The fall in ACLA titres after either surgical
resection of the tumour or chemotherapy treatment in
our patients, and in other reported cases (Duncombe et
al., 1987; Levine et al., 1987; Ciaudo et al., 1991), can
be explained by either decreased antigenic stimulation of
the reduced tumour mass or the immunosuppressed pro-
duction of ACLA induced by therapy.
2. Production of monoclonal immunoglobulins with LAC
or ACLA activities. The association ofmonoclonal IgM
and LAC was first reported by Thiagarajan et al.
(1980). Later, Bellotti et al. (1989) reported three
patients with monoclonal gammopathy in whom the
paraproteins (IgG/kapa or of a IgM/lambda) were res-
ponsible for the anticoagulant activity by interacting
with the thromboplastin phospholipid. These two
reports and others (Duhrsen et al., 1987; Watts et al.,
1989; Ciaudo et al., 1991; Wisloff et al., 1991) support
the assumption that, in some patients with monoclonal
gammopathy, the monoclonal immunoglobulin may
possess anti-cardiolipin activity. Five of our patients
had a monoclonal spike of the IgG class and elevated
levels of ACLA. Although we did not find that the
monoclonal gammaglobulins showed anti-cardiolipin
activity, it is of note that in four out of these five
patients the anti-cardiolipin was of the same isotype
(IgG).
3. Disappearance of ACLA after treatment of the tumour
may support the hypothesis ofdirect secretion ofACLA
from the tumour cells. But, in a case of thymoma
associated with ACLA (Levine et al., 1987), short-term
tissue culture of the thymoma cells did not show such
ACLA synthlesis. It has recently been suggested that
treatment of cancer (solid and non-solid), including the
use of chemotherapeutic agents and hormones, may
contribute to the increased risk of thromboembolism in
these patients (Legrand et al., 1986; Schreiber and
Kapp, 1986; Levine et al., 1988). However, in our study,
such an effect was not noticed.
In this study we demonstrated in patients with malignancy
the association of ACLA with TE. We did not analyse
protein C, protein S and antithrombin III, since recent
studies have shown that these factors do not correlate with
the presence of ACLA in thrombotic patients (Montalban et
al., 1991; Rivier et al., 1994). In addition, these coagulation
tests should always be tested off warfarin. Since all our
ACLA-positive TE patients were immediately anticoagulated
for secondary prevention of additional TE events, such an
analysis was omitted. The question of primary prophylaxis in
ACLA-positive patients is not yet conclusive and is the sub-
ject of our further study.
In conclusion, a significantly high prevalence of anticar-
diolipin antibodies was found in patients with various types
of malignancies as compared with age- and sex-matched
controls. ACLA-positive cancer patients, especially those
with high ACLA levels, had a significantly higher rate of
venous and/or arterial TE events than ACLA-negative cancer
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patients. This suggests that elevated levels of ACLA may be
one of the contributory factors in the paraneoplastic TE
complications occurring in patients with neoplasm.
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